FDx Advisors Inc. increased its holdings in Agilent Technologies, Inc. (NYSE:A) by 17.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,432 shares of the medical research company’s stock after purchasing an additional 2,170 shares during the period. FDx Advisors Inc.’s holdings in Agilent Technologies were worth $927,000 as of its most recent SEC filing.
Several other large investors have also made changes to their positions in A. Bank of Montreal Can grew its position in Agilent Technologies by 27.9% during the second quarter. Bank of Montreal Can now owns 227,044 shares of the medical research company’s stock valued at $13,467,000 after acquiring an additional 49,583 shares during the period. Creative Planning grew its position in Agilent Technologies by 9.1% during the second quarter. Creative Planning now owns 13,046 shares of the medical research company’s stock valued at $774,000 after acquiring an additional 1,085 shares during the period. Eqis Capital Management Inc. purchased a new stake in Agilent Technologies during the second quarter valued at about $484,000. Oregon Public Employees Retirement Fund grew its position in Agilent Technologies by 170.7% during the second quarter. Oregon Public Employees Retirement Fund now owns 91,659 shares of the medical research company’s stock valued at $5,436,000 after acquiring an additional 57,800 shares during the period. Finally, LS Investment Advisors LLC grew its position in Agilent Technologies by 17.4% during the second quarter. LS Investment Advisors LLC now owns 9,685 shares of the medical research company’s stock valued at $574,000 after acquiring an additional 1,434 shares during the period.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies, Inc. (A) Stake Raised by FDx Advisors Inc.” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.themarketsdaily.com/2017/11/16/agilent-technologies-inc-a-stake-raised-by-fdx-advisors-inc.html.
Agilent Technologies (NYSE:A) last released its quarterly earnings results on Tuesday, August 15th. The medical research company reported $0.59 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.07. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The business had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the previous year, the firm posted $0.49 earnings per share. The company’s revenue was up 6.7% compared to the same quarter last year. analysts forecast that Agilent Technologies, Inc. will post 2.32 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be paid a $0.149 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a dividend yield of 0.89%. Agilent Technologies’s payout ratio is 27.32%.
A has been the topic of a number of recent research reports. Morgan Stanley restated an “overweight” rating on shares of Agilent Technologies in a research note on Tuesday. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective on the stock in a research note on Tuesday, October 31st. Robert W. Baird restated a “buy” rating and set a $70.00 price objective on shares of Agilent Technologies in a research note on Friday, October 20th. Cowen and Company restated a “hold” rating and set a $65.00 price objective on shares of Agilent Technologies in a research note on Thursday, September 28th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $68.00 price objective on shares of Agilent Technologies in a research note on Tuesday, September 26th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $66.70.
In other Agilent Technologies news, insider Mark Doak sold 12,421 shares of the company’s stock in a transaction that occurred on Friday, August 18th. The stock was sold at an average price of $61.57, for a total transaction of $764,760.97. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Didier Hirsch sold 15,555 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $66.00, for a total value of $1,026,630.00. Following the sale, the chief financial officer now owns 178,557 shares in the company, valued at approximately $11,784,762. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,713 shares of company stock worth $9,682,305.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A).
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.